Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor. Hepatology-2014



Similar documents
Alcoholic hepatitis. Dr.Abonyi Margit

Hepatitis C Class Review

Molecular Diagnosis of Hepatitis B and Hepatitis D infections

Viral Hepatitis Case Report

Monitoring of Treatment of viral hepatitis C

HBV DNA < monitoring interferon Rx

PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN?

Robert G. Knodell, M.D. Maryland Chapter, American College of Physicians Fb February 3, 2012

LA TERAPIA PER HBV ed HCV Differenze di Genere? Alfredo Alberti. Dipartimento di Medicina Molecolare UOC Medicina Generale VIMM Università di Padova

1.1.2 Amend the that the Special Authority relating to tenofovir for use in pregnancy for postpartum care;

Therapy of decompensated cirrhosis Pre-transplant for HBV and HCV

PURPOSE: To define the criteria to be used to determine the medical necessity of antiviral therapy in the treatment of Chronic Hepatitis B.

Focus on Transplantation: Treatment Post-transplant for HBV and HCV

Peg-IFN and ribavirin: what sustained virologic response can be achieved by using HCV genotyping and viral kinetics?

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

Management of Chronic Hepatitis B: 2012 Update

Optimising therapy in chronic hepatitis B: Switch or add treatment

Hepatitis B and C Co-infection. Mark Hull MHSc, FRCPC Clinical Assistant Professor Division of AIDS

UPDATE ON NEW HEPATITIS C MEDICINES

Treatment for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection - Danish national guidelines 2011

PRIOR AUTHORIZATION PROTOCOL FOR HEPATITIS C TREATMENT

HBV screening and management in HIV-infected children and adolescents

2015 Outpatient Chronic Hepatitis B Management

HBV Treatment Guidelines. By: Prof.Dr. Abdelfatah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine

Impact of natural boostering on long-term protection against hepatitis B after newborn (HBsAg + mothers) vaccination.

Stepwise Approach for Detecting, Evaluating, and Treating Chronic Hepatitis B Virus Infection

Primary Care for Hepatitis B and C:

EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B September, 2002 Geneva, Switzerland Consensus statement (Short version)

Hepatitis C Glossary of Terms

Hepatitis Update Brendan M. McGuire, MD UAB Liver Center

Clinical Criteria for Hepatitis C (HCV) Therapy

Chronic hepatitis B (CHB) remains an important public SPECIAL REPORT

BHIVA Guidelines for the Management of Hepatitis Virus Infection in Adults

HEPATITIS COINFECTIONS

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

Hepatitis C Treatment Advocacy: Ireland. Brian O Mahony

The availability of newer antiviral agents, as

Viral Hepatitis APHL survey report

Update on Hepatitis C. Sally Williams MD

Hepatitis C Virus (HCV)

MEDICAL POLICY STATEMENT

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

ROYAL HOSPITAL FOR WOMEN

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics

Clinical Case n. 3 Massimo Puoti AO Ospedale Niguarda Ca Granda Milano, Italy

AASLD PRACTICE GUIDELINES Chronic Hepatitis B: Update 2009

Hepatitis C Monitoring and Complications (and Treatment!) Dr Mark Douglas

Hepatitis B: Objectives. Hepatitis C: Objectives. Hepatitis B: Natural History. Hepatitis B is a DNA virus and is NOT curable.

Hepatitis B and C What Is New In Perinatal Transmission?

Treatment of Hepatitis B

Update on hepatitis C: treatment and care and future directions

AASLD PRACTICE GUIDELINES Chronic Hepatitis B

TESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL

HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM: Page 1 of 3 Patient Information. Diagnosis Acute Hep C Chronic Hep C Hepatocellular Carcinoma

Virology. Behandlung der Hepatitis B. HBV Genome. HBV life cycle. HBV Genotypes. Natural History. 8 genotypes: A, B, C, D, E, F, G, H

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

Briefing Note: Hepatitis B & Hepatitis C. Summary:

Liver Disease and Therapy of Hepatitis B Virus Infections

Transmission of HCV in the United States (CDC estimate)

Managing Treatment Naive Pa/ents in the DAA Era. An Interac/ve Case study

EASL Clinical Practice Guidelines: Management of chronic hepatitis B

Post AASLD Update in HCV Torino, 10 Gennaio Fattori che possono influenzare il trattamento: RVR e Lead in

Current Opinion in Hepatitis C Treatment

Treatment Strategies of Hepatitis B in China

1. A 19 year old Caucasian male is referred to you because he recently developed acute HBV.

AASLD PRACTICE GUIDELINE UPDATE Chronic Hepatitis B: Update 2009

Disclosure of Conflicts of Interest Learner Assurance Statement:

Newly Diagnosed: HEPATITIS C. American Liver Foundation Support Guide

PHARMACY PRIOR AUTHORIZATION

Objectives. Hepatitis C: The new era of screening and treatment. Distribution of HCV genotypes 11/1/2014. History of HCV diagnosis and screening

Update on Pharmacotherapy of Chronic Hepatitis B and C

Clinical Criteria for Hepatitis C (HCV) Therapy

Cirrhosis and HCV. Jonathan Israel M.D.

Preamble. Introduction. Marc G. Ghany, 1 David R. Nelson, 2 Doris B. Strader, 3 David L. Thomas, 4 and Leonard B. Seeff 5 *

Hepatitis C Infection In Singapore

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

NEW DRUGS FOR THE TREATMENT OF HEPATITIS C. Marcella Honkonen, PharmD, BCPS AzPA Annual Convention. Sunday, June 29 th, 2014 (1:15-2:15)

DE VERSCHILLENDE ANTIVIRALE MIDDELEN EN HUN WERKINGSMECHANISME

HEPATITIS B VIRUS (HBV) & HEPATITIS C VIRUS (HCV)

Ledipasvir/Sofosbuvir (Harvoni) for Treatment of Hepatitis C

Physician s Guide to. Hepatitis B. a silent killer. Developed by the Asian Liver Center at Stanford University

Hepatitis C Second Generation Antivirals (Harvoni, Technivie TM, Viekira Pak ) Prior Authorization - Through Preferred Agent(s) Program Summary

In the last decade, important advances have been made

Viral Hepatitis Prevention Board Meeting November The Netherlands: Hepatitis C treatment guidelines

Medical publications on HBV and HCV Coinfection

PRIOR AUTHORIZATION POLICY

Hepatitis Update. Study 110: SVR at post-treatment week 24 (SVR24) Jürgen Rockstroh, MD. No ART EFV/TDF/FTC ART/r/TDF/FTC Total

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection

HEPATITIS B VIRUS II. HEPATITIS B VIRUS RECOMMENDATIONS:

Long-term Results of Pegylated Interferon alfa-2a and Tenofovir for Hepatitis B

boceprevir 200mg capsule (Victrelis ) Treatment naïve patients SMC No. (723/11) Merck Sharpe and Dohme Ltd

CASG HBV Study Richard B. Pollard, MD David M. Asmuth, MD Division of Infectious Diseases University of California Davis Medical Center Sacramento, CA

TAYSIDE BLOOD BORNE VIRUS (BBV) MANAGED CARE NETWORK (MCN) Clinical Guidelines for the Management of Hepatitis C. April 2012

The Influence of Steatosis and Conjugated Factors on the Response to Antiviral Therapy in Chronic Hepatitis Band C

The Natural History of Chronic Hepatitis B Virus Infection

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

The question and answer session is not available after the live webinar.

Transcription:

Dr. Abonyi Margit PhD SE 1st Medical Clinic Associate Professor Hepatology-2014

Other virus hepatitis Epstein-Barr vírus Cytomegalo vírus Herpes simplex vírus Coxsackie vírus

Hepatitis B vírus Hepadnavírus, diameter: 42nm,DNS

Hepatitis B Incubation: mean:30 days (14-45) Transmission: by blood,blood product,vertikal,sexual road Antigens: HBsAg and HBeAg Antibodies:anti-HBs,anti-HBe,anti- HBc,anti-HBc IgM Fulminant:0.5-1% Spontan recovery: 90%

Hepatitis B Chronic active hepatitis:10% Cirrhosis: 1%- Vaccination: activ and és passiv

Hepatitis B therapy Peginterferon-alfa2a: 180 ug / week/sc 48 weeks Lamivudine:100mg/ day (resistency-ymdd-75% in few years) Adefovir:10 mg/ day (resistency:29%-during 5 years ) Entecavir:1 mg /day (at naive pts:0.5 mg /day) (R:1.2 %) Telbivudine:600 mg/day (R:2-5%-after 1 year) Tenofovir: 300 mg /day( R: not known until yet)

Hepatitis B HBeAg + pts:after the HBeAg seroconversion more 12 months HBeAg pts: long time, lifelong,it depends of the HBV DNS PCR results In decompensated cirrhosis:entecavir,tenofovir,adefovir or Telbivudine lifelong treatment!!! Lactate acidosis danger!

Hepatitis B In pregnancy: in the last trimester could be treated by hyperimmunserum or Tenofovir or Lamivudine ortelbivudine at the time of the delivery of the babythe mother and baby will be negative, but at the newborn you should give active and passive immunisation

Hepatitis B profilaxis Passive: HBIG-high titer anti-hbs treatment 0.1 ml/kg or 5 ml 12 (36) hours after the child birth or exposition Active: 3x- 0., 1., and 6. month ( 10 or 20 ug HBsAg)- effective,if the anti-hbs titer is higher, than 100 IU Before the immunisation we must know about current HBV infection(hbsag, anti-hbc and anti-hbs)

Hepatitis D Viroid Diameter:36 nm,rns Together with HBV infection or super - infection after HBV infection Antigen: HDAg Antibody: anti-hdv, anti HDV IgM

Hepatitis D Fulminant: 1-3-25-30% Spontan recovery:50-80% Chronic type:: 20-50 % Develop cirrhosis: 10 % -25 % No vaccination possibility 300 million HBV +, 5 % HDV+,too!!!

Hepatitis C treatment 2011 Peginterferon alfa 2a or 2b sc./ week and Ribavirin 13.6-14 mg / kg per os, /day SVR: Genotype 1,4 ( 48 week th)- 46-57 % Genotype 2,3( 24 week th)- 76-82 % 40-70 %-of the HCV+ pts is not treated USA: only 15% of HCV+pts is treated!

Hepatitis C 2011 or 2012 new treatment possibilities: Boceprevir th. ( 28 and 36 weeks treatment ) SVR: 78-91% Telaprevir th. ( 24 weeks treatment) SVR: 77-89 %

Hepatitis C result -definition RVR: Rapid Virological Response- the HCV RNA PCR is negative in the 4.week of treatment EVR: Early Virological Response-the HCV RNA PCR is negative in the 12. week of the treatment EOT:End of Teatment Response- the HCV RNA PCR is negative of the end of treatment in the 48.week

Hepatitis C SVR: Sustained Virological Response- the HCV RNA PCR is negative after 24 weeks of the end of treatment ( in the 72.week)) RGT:Response Guided Therapy-during the treatment we decide to change the treatment knowing the HCV RNA PCR result DAA: Direct Acting Agents: Boceprevir, Telaprevir ( NS 3 protease inhibitors)

Hepatitis C IL 28B genetic test C/C good allel,good treatment result C/T worser result T/T - worst result In C/C allel is a spontan recovery possibility-after Ltx (liver transplantation) is also helpful

Hepatitis C modern algorytm of treatment 2,3 genotypes, if it is RVR, the th. 12-16 weeks long, 1 genotype:if it is RVR, the therapy 24 or 28 or 36 weeks long, 1 genotype: if it is late response,the PCR is negatíve only at the 24.weeks,the therapy 72 weeks long

2011-hepatology centers must done: HCV RNA and HBV DNA PCR- Quantiplex measuring Virus genotypes monitoring IL 28B polymorphism checking Fibroscan and US,FNAB, core biopsy

2011 NEW GOALS At the time of diagnosis, later at week 0.,4.,12.,24.,48. and 72. PCR!( 7x)-in HCV+ pts HBV DNA PCR must we measure at the time of the diagnosis and every 6.month of the treatment

NASH 30-46 %, over40 years BMI > 30 kg/m 2 II.DM, glucose intolerancy,niddm HOMA index > 2 Hypertony ALAT-elevated CK-18 fragment is elevated (250-2250 U/l)

NASH therapy Daily 800 mg E vitamin ACE inhibitors Statins US and Fibroscan is important ACI Doppler UH and Aspirin protect!